CV Sciences Enters Material Definitive Agreement

TL;DR

CV Sciences signed a big deal on Feb 12, 2025. 8-K filed Sept 18, 2025.

AI Summary

CV Sciences, Inc. entered into a Material Definitive Agreement on February 12, 2025. The company, formerly known as CannaVEST Corp. and Foreclosure Solutions, Inc., filed an 8-K report on September 18, 2025, detailing this agreement. The filing also includes financial statements and exhibits related to the agreement.

Why It Matters

This filing indicates a significant new contract or partnership for CV Sciences, Inc., which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The filing reports a material definitive agreement, which could represent a significant new business opportunity or obligation, but the specifics of the agreement are not detailed in this summary.

Key Players & Entities

• CV Sciences, Inc. (company) — Registrant
• CannaVEST Corp. (company) — Former company name
• Foreclosure Solutions, Inc. (company) — Former company name
• February 12, 2025 (date) — Date of earliest event reported
• September 18, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $1,600,000 — ote in the original principal amount of $1,600,000 (the "Note"). The Note carries an origi
• $400,000 — arries an original issuance discount of $400,000 which was deducted from the proceeds of
• $1,200,000 — rchase price received by the Company of $1,200,000. In addition, the Company paid $10,000
• $10,000 — ,200,000. In addition, the Company paid $10,000 to the Investor to cover its legal fees
• $106,666.67 — nthly redemption amount consists of (i) $106,666.67 of the outstanding principal amount of
• $0 — first 3 monthly redemption dates, (ii) $0 of the outstanding principal amount of
• $150,000 — st, if any, (c) provide to the Investor $150,000 in cash. Other than as modified above

Filing Documents

• cvsi-20250912.htm (8-K) — 50KB
• cvsi-ex10_1.htm (EX-10.1) — 31KB
• 0001193125-25-207436.txt ( ) — 176KB
• cvsi-20250912.xsd (EX-101.SCH) — 22KB
• cvsi-20250912_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement On February 12, 2025, CV Sciences, Inc., a Delaware corporation (the "Company") entered into a Note Purchase Agreement ("Purchase Agreement") with an institutional investor ("Investor"), pursuant to which the Company issued and sold to the Investor a Secured Promissory Note in the original principal amount of $1,600,000 (the "Note"). The Note carries an original issuance discount of $400,000 which was deducted from the proceeds of the Note received by the Company which resulted in a purchase price received by the Company of $1,200,000. In addition, the Company paid $10,000 to the Investor to cover its legal fees. The Company entered into an agreement ("Agreement") with the Investor on September 12, 2025 ("Effective Date"). The Agreement amended the Note and the Purchase Agreement to, among other things: (a) provide for a new maturity date of February 12, 2027, (b) provide that the monthly redemption amount consists of (i) $106,666.67 of the outstanding principal amount of the Note on each of the first 3 monthly redemption dates, (ii) $0 of the outstanding principal amount of the note on each of the next 6 monthly redemption dates, and (iii) $106,666.67 of the outstanding principal amount of the Note on each of the subsequent 12 monthly redemption dates, in each case plus accrued but unpaid interest, if any, (c) provide to the Investor $150,000 in cash. Other than as modified above, the terms of the Note and Purchase Agreement remain in full force and effect. The preceding descriptions of the terms of the Agreement do not purport to be complete and are qualified in their entirety by the full text of the Agreement which is filed as an exhibits to this report and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits 10.1 Agreement dated September 12, 2025 (confidential portions of the exhibit have been omitted where indicated) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CV SCIENCES, INC. Date: September 18, 2025 By: /s/ Joseph Dowling Joseph Dowling Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR